Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas P Restifo

Showing results (51-60 of 260) with videos related to

Pageof 26
Sort By:
Current Protocols in Immunology|February 3, 2015
Mouse model for pre-clinical study of human cancer immunotherapyZhiya Ya, Yared Hailemichael, Willem Overwijk, et al.
The New England Journal of Medicine|September 5, 2008
Cancer immunotherapySteven A Rosenberg, Mark E Dudley, Nicholas P Restifo
Science (New York, N.Y.)|January 13, 2018
Silencing stemness in T cell differentiationAmanda N Henning, Christopher A Klebanoff, Nicholas P Restifo
Nature Reviews. Clinical Oncology|November 12, 2014
Immunotherapy: Treatment of aggressive lymphomas with anti-CD19 CAR T cellsChristopher A Klebanoff, Tori N Yamamoto, Nicholas P Restifo
Cell|October 30, 2020
Strength in Numbers: Identifying Neoantigen Targets for Cancer ImmunotherapyRigel J Kishton, Rachel C Lynn, Nicholas P Restifo
Nature Reviews. Immunology|March 23, 2012
Adoptive immunotherapy for cancer: harnessing the T cell responseNicholas P Restifo, Mark E Dudley, Steven A Rosenberg
Nature Medicine|September 2, 2004
Cancer immunotherapy: moving beyond current vaccinesSteven A Rosenberg, James C Yang, Nicholas P Restifo
Immunological Reviews|January 5, 2011
Therapeutic cancer vaccines: are we there yet?Christopher A Klebanoff, Nicolas Acquavella, Zhiya Yu, et al.
Current Opinion in Immunology|October 28, 2021
Next generation immunotherapy: enhancing stemness of polyclonal T cells to improve anti-tumor activityRigel J Kishton, Suman K Vodnala, Raul Vizcardo, et al.
Cancers|July 12, 2025
Regenerative Immunotherapy for Cancer: Transcription Factor Reprogramming of Tumor-Specific T CellsTyler R McCaw, Nicholas P Restifo, Kathrin Plath, et al.
Pageof 26

Showing results (51-60 of 260) with videos related to

Sort By:
Pageof 26
Current Protocols in Immunology|February 3, 2015
Mouse model for pre-clinical study of human cancer immunotherapyZhiya Ya, Yared Hailemichael, Willem Overwijk, et al.
The New England Journal of Medicine|September 5, 2008
Cancer immunotherapySteven A Rosenberg, Mark E Dudley, Nicholas P Restifo
Science (New York, N.Y.)|January 13, 2018
Silencing stemness in T cell differentiationAmanda N Henning, Christopher A Klebanoff, Nicholas P Restifo
Nature Reviews. Clinical Oncology|November 12, 2014
Immunotherapy: Treatment of aggressive lymphomas with anti-CD19 CAR T cellsChristopher A Klebanoff, Tori N Yamamoto, Nicholas P Restifo
Cell|October 30, 2020
Strength in Numbers: Identifying Neoantigen Targets for Cancer ImmunotherapyRigel J Kishton, Rachel C Lynn, Nicholas P Restifo
Nature Reviews. Immunology|March 23, 2012
Adoptive immunotherapy for cancer: harnessing the T cell responseNicholas P Restifo, Mark E Dudley, Steven A Rosenberg
Nature Medicine|September 2, 2004
Cancer immunotherapy: moving beyond current vaccinesSteven A Rosenberg, James C Yang, Nicholas P Restifo
Immunological Reviews|January 5, 2011
Therapeutic cancer vaccines: are we there yet?Christopher A Klebanoff, Nicolas Acquavella, Zhiya Yu, et al.
Current Opinion in Immunology|October 28, 2021
Next generation immunotherapy: enhancing stemness of polyclonal T cells to improve anti-tumor activityRigel J Kishton, Suman K Vodnala, Raul Vizcardo, et al.
Cancers|July 12, 2025
Regenerative Immunotherapy for Cancer: Transcription Factor Reprogramming of Tumor-Specific T CellsTyler R McCaw, Nicholas P Restifo, Kathrin Plath, et al.
Pageof 26